Martin is an experienced economics master known for refining and managing companies. He has led two successful company listings on Nasdaq First North and Spotlight Stock Market. With expertise in hypothermia treatment and medical technology products, Martin has been active in the medical technology field since the early 2000s. He is currently a board member of Bio Medical Lund AB.
Jon holds an engineering degree from the Faculty of Engineering at LTH with a specialization in energy engineering. He has an impressive background, boasting 25 years of experience in the medical device industry. During this time, he served as Development Manager for both Gambro AB and Atos Medical AB.
Lotta has a diploma in accounting from Stockholm University of Business. She has worked in the accounting field in a number of different roles, most recently as financial manager at Bona AB and before that as controller at Smurfit Kappa AB, accounting manager and accounting manager at Mekonomen Group AB and financial manager at Woody Bygghandel.
Thomas holds an MSc Engineering degree from the University of Kristianstad, specializing in Polymer Technology. With over 18 years of experience in International Research and Development, the last 10 years were dedicated exclusively to the medical device industry. He has held senior positions at esteemed medical device companies, including Arjo and Stryker (formerly Jolife – Lucas device). In 2021, he became the CTO at Prosta Lund before joining BrainCool.
Hakan holds a Pharmacology degree from the University of Gothenburg and has amassed over 10 years of experience as a quality manager in the medical device industry. He became part of BrainCool AB in 2017 and earned a promotion to QAD in 2021. Before joining BrainCool, Hakan served in clinical and quality roles at Dignitana, gaining valuable expertise within the medical device industry.
Mohammad earned his PhD in biomedical engineering from the University of Western Ontario in Canada in 2014. His research focused on brain cooling technology and optical brain thermometry techniques. With over 14 years of experience in medical device development, he has led innovative projects targeting cardiovascular diseases and Chronic Obstructive Pulmonary Diseases. Mohammad joined the BrainCool management team in 2018.
Martin is an experienced economics master known for refining and managing companies. He has led two successful company listings on Nasdaq First North and Spotlight Stock Market. With expertise in hypothermia treatment and medical technology products, Martin has been active in the medical technology field since the early 2000s. He is currently a board member of Bio Medical Lund AB.
Holdings: 1,162,687 shares
Hans has extensive experience from global pharmaceutical and medical technology companies in various positions with a focus on business development and corporate governance. He has extensive experience in business operations in Asian markets, especially Japan, China and South Korea. Hans is considered independent in relation to the Company's major shareholders but dependent in relation to the Company and company management. Other ongoing assignments: Board member in HANOVA Healthcare Development AB.
Holdings: 399,014 shares
Oscar, co-founder and co-owner of Bolite Bostäder Holding AB, holds an economics degree from the Stockholm School of Economics with a finance specialization. With 17 years of experience, including six years as an investment banker at Deutsche Bank/Barclays Capital in London, he has been actively involved in running Bolite Bostäder for the past nine years. Oscar is considered independent in relation to the Company, its management, and major shareholders. His other ongoing roles include board member and CEO positions within the Bolite Group, as well as a board member of Thantor AB.
Holdings: 4,319,476 shares through Bolite Invest AB
Roger served as the director of the Regional Cancer Center Stockholm/Gotland from 2012 to 2018. Prior to that, he held positions at Karolinska University Hospital and Umeå University, specializing in radiation sciences and oncology. He has also held various national and international roles in cancer research, advisory boards, and pharmaceutical committees. Currently, he is a board member and chairman of Aktiebolaget Altimed and the scientific council Sjöbergstiftelsen. While considered independent from the Company's major shareholders, he is dependent on the Company and its management.
Holdings: 57,000 shares
